Article info
PDFEditors’ commentary
Highlights from this issue
Citation
Highlights from this issue
Publication history
- Accepted June 22, 2020
- First published July 19, 2020.
Online issue publication
July 28, 2020
Article Versions
- Previous version (19 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell - related adverse events
- Study protocol for THINK: a multinational open - label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types
- The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
- Emerging immunotherapies in multiple myeloma
- Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
- Treatment of patients with relapsed or refractory CD19 + lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD 28.4-1BBzeta retroviral vector: a unicentre phase I / II clinical trial protocol
- Modulating TNFα activity allows transgenic IL15 - Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
- The Great Debate at ‘ Immunotherapy Bridge ’, Naples, December 5, 2019